Immunome (NASDAQ:IMNM) Earns Outperform Rating from Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating reiterated by Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They presently have a $33.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 251.81% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Piper Sandler decreased their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens assumed coverage on shares of Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome presently has a consensus rating of “Buy” and a consensus target price of $28.83.

Immunome Price Performance

Immunome stock opened at $9.38 on Monday. The firm has a 50-day moving average of $11.72 and a 200-day moving average of $12.98. The company has a market cap of $585.47 million, a price-to-earnings ratio of -1.16 and a beta of 1.90. Immunome has a one year low of $8.97 and a one year high of $30.96.

Insider Activity

In other Immunome news, CEO Clay B. Siegall purchased 66,057 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the purchase, the chief executive officer now owns 485,693 shares in the company, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Robert Lechleider acquired 15,805 shares of Immunome stock in a transaction on Thursday, November 21st. The shares were bought at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the transaction, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 102,862 shares of company stock valued at $978,045 over the last three months. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC acquired a new stake in Immunome during the second quarter worth approximately $81,000. Arizona State Retirement System increased its stake in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the period. AQR Capital Management LLC lifted its holdings in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after purchasing an additional 4,129 shares during the last quarter. Intech Investment Management LLC bought a new stake in Immunome in the 3rd quarter valued at $219,000. Finally, Profund Advisors LLC acquired a new position in Immunome in the 2nd quarter valued at $262,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.